IDO1 and Alzheimer disease: Altogether, these results suggest that the enhanced immunoregulatory properties of human AD-MSC treated with PP11 or GSK3787 compared to naïve MSC or GSK3787 are associated with the higher expression of ANGPTL4 and COX2 and the higher activity of IDO.